Generics Bulletin is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Fresenius Kabi Unveils 2026 Strategy With Focus On Business Not Region

Increased Focus On Biosimilars And Peptides Under New CEO Michael Sen

Executive Summary

Fresenius Kabi has revealed a five-year strategic roadmap, driven by its fresh management team, including broadly to increase the injectables specialist’s global competitiveness and advance organizational effectiveness.

You may also be interested in...



Kabi Urges Caution And Patience On Subcutaneous Bortezomib Launch

Fresenius Kabi’s Q1 call spanned its recent launch of a generic version of Takeda’s Velcade subcutaneous injectable to the company’s continued ambitions in biosimilars, with the German firm’s acquisition of a controlling stake in mAbxience scheduled to close by the middle of the year.

Fresenius Kabi Acquires Ivenix For $240M To Expand Presence In Infusion Pump Market

Fresenius Kabi will pay up to $240m for Massachusetts-based Invenix to expand its infusion pump portfolio. Simultaneously, the company also made a major move to bolster its biosimilars business by acquiring a majority stake in mAbxience.

Fresenius Puts Kabi At The Top As It Ponders Best Use Of Cash

The Fresenius group has all but ruled out any equity investment in Fresenius Kabi, as it looks to make the best use of its capital and “tap new capital sources” to drive growth.

Related Content

Topics

Related Companies

Latest News
UsernamePublicRestriction

Register

GB151388

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel